Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D9JW
|
|||
| Former ID |
DAP000618
|
|||
| Drug Name |
Ketorolac
|
|||
| Synonyms |
Ketoralac; Ketorolaco; Ketorolacum; Macril; Ketorolaco [Spanish]; Ketorolacum [Latin]; RS 37619; Acular (TN); Ketorolac (INN); Ketorolac [INN:BAN]; RS-37619; Toradol (TN); (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; (+-)-Ketorolac; (+-)-isomer; (+/-)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid; 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro; 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid; 5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid; 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Postoperative inflammation [ICD-11: 1A00-CA43.1] | Approved | [1] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
Laboratorios Syntex SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H13NO3
|
|||
| Canonical SMILES |
C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
|
|||
| InChI |
1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
|
|||
| InChIKey |
OZWKMVRBQXNZKK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 74103-06-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9274, 5316934, 7979681, 8152424, 12013083, 14774471, 29222945, 46507019, 48416148, 49698948, 50040043, 50559242, 53787558, 56313647, 57322012, 85787389, 87245106, 90341692, 92719330, 96024794, 99281833, 103168363, 103922837, 104304637, 118314823, 124749910, 124896716, 125357028, 126449597, 126449602, 126621065, 126628266, 126648434, 126657726, 126670368, 126670856, 128885449, 131939830, 134337908, 135011243, 135039632, 136351611, 137035346, 142342166, 160654547, 160963811, 162178870, 162631206, 163414850, 164827307
|
|||
| ChEBI ID |
CHEBI:76223
|
|||
| ADReCS Drug ID | BADD_D01232 | |||
| SuperDrug ATC ID |
M01AB15; S01BC05
|
|||
| SuperDrug CAS ID |
cas=074103063
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.76; p = 0.008). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.764; p = 0.034). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.74; p = 0.042). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.651; p = 0.002). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.71; p = 0.024). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.737; p = 0.029). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -0.798; p = 0.043). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.636; p = 0.008). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.731; p = 0.013). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ketorolac tromethamine can be metabolized by Clostridium sp. (log2FC = -0.513; p = 0.028). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin G/H synthase (COX) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 3 | Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.